2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

1950 HBV infection and clinical outcome of frontline polatuzumab vedotin‑based chemoimmunotherapy in diffuse large B‑cell lymphoma: A multicenter real‑world study

Mengqiu Wu, Panpan LIU2, Peng SUN, PhD3, Yajun Li4, Yan Qin5, Xiangjun Fu6, Guinian Huang7, Yudan Wu8, Ning Su9, Jihao Zhou, MD10, Hui Li11, Qian Zhang12, Zhi Guo, PhD13, Chan Long14, Zhiqiang Sun15, Bo Lu16, Xudong Jiang17, Suyun Wang18, Xiaotao Wang19, Naping Tang20, Limei Li21, Renzhou Shi22, Xiaoqing Li23, Zhiming Li, MD24
1 Sun Yat-Sen University Cancer Center, Guangzhou, China
2 Sun Yat-Sen University Cancer Center, Guangzhou, China
3 Sun Yat-Sen University Cancer Center, Guangzhou, China
4 Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
5 National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
6 Hainan General Hospital, Haikou, China
7 Zhongshan Hospital Affiliated to Sun Yat-Sen University, Zhongshan, China
8 Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
9 Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
10 The Second Clinical Medical College, The First Affiliated Hospital, Shenzhen People's Hospital, Jinan University, Southern University of Science and Technology), Shenzhen, China
11 Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China
12 Peking University Shenzhen Hospital, Shenzhen, China
13 Affiliated Nanshan Hospital of Shenzhen University, Shenzhen, China
14 Huizhou First Hospital, Huizhou, China
15 Shenzhen Hospital of Southern Medical University, Shenzhen, China
16 The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China
17 The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
18 Longhua District Central Hospital, Shenzhen, China
19 Affiliated Hospital of Guilin Medical University, Guilin, China
20 Huaihua Cancer Hospital, Huaihua, China
21 The Second Affiliated Hospital of Hainan Medical University, Haikou, China
22 The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
23 The First Affiliated Hospital of Shenzhen University/Shenzhen Second People's Hospital, Shenzhen, China
24 Sun Yat-Sen University Cancer Center, Guangzhou, China

Background

Based on the POLARIX trial, polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) has become a first-line standard of care in diffuse large B-cell lymphoma (DLBCL). Hepatitis B Virus (HBV) reactivation is a well-recognized complication of rituximab-containing chemoimmunotherapy, affecting 1.5%–25.9% of patients with resolved HBV infection; however, its incidence in the context of Pola-R-CHP has yet to be characterized. Furthermore, data on the impact of HBV infection on clinical outcomes in patients receiving first-line Pola-R-CHP remain scarce, and current international guidelines offer disparate recommendations on antiviral prophylaxis for this population. To address these gaps, we conducted a multicenter real-world study to evaluate HBV reactivation rates, prophylactic antiviral use, and treatment outcomes in DLBCL patients treated with upfront Pola-R-CHP, stratified by baseline HBsAg status.

Methods

Eligible patients were aged 18 years or older, with histologically confirmed DLBCL and had received at least one cycle of frontline Pola-based Chemoimmunotherapy from April 2023 to May 2025 at 21 centers in China. Baseline HBsAg and HBV-DNA results were required for inclusion. We prespecified two categories of HBV infection status: HBsAg-positive and HBsAg-negative including HBsAg-negative/HBcAb-positive (resolved HBV) and HBsAg-negative/HBcAb-negative (HBV-naïve). For HBsAg-positive patients, HBV reactivation was defined as any of: a ≥2 log (100-fold) rise in HBV DNA from baseline; HBV DNA ≥3 log (1,000) IU/mL with undetectable baseline; or HBV DNA ≥4 log (10,000) IU/mL in the absence of baseline data. For HBsAg-negative/HBcAb-positive patients, reactivation was defined as HBsAg seroreversion or emergence of detectable HBV DNA. Hepatitis attributable to HBV reactivation was defined as ALT ≥3× baseline and >100 U/L, concomitant with or secondary to HBV reactivation, after ruling out acute infection with other hepatitis viruses and systemic conditions. The primary endpoints were the incidence of HBV reactivation. Secondary endpoints included the complete response (CR) rate at end of treatment (EOT), progression-free survival (PFS), and overall survival (OS).

Results

A total of 107 patients with complete baseline HBsAg and HBV-DNA data were enrolled, of whom 45 (42.1%) were HBsAg-positive and 62 (57.9%) were HBsAg-negative. Compared with HBsAg-positive patients, those who were HBsAg-negative were significantly older (P=0.010) and had a lower proportion of intermediate and high-risk (IPI 3~5) (P=0.048). Other baseline characteristics were balanced between the two groups, including sex (P=0.305), Ann Arbor stage III–IV (P=0.510), ECOG performance status (P=0.788), extranodal involvement sites number (P=0.219), liver involvement (P=0.739), elevated LDH (P=0.218), and cell-of-origin subtype (P=0.123).

HBV reactivation occurred in 3 of 45 HBsAg-positive patients and in 7 of 56 HBsAg-negative patients (6.7% vs 12.5%; P=0.505). No cases of hepatitis associated with HBV reactivation were observed. Among all 10 patients who experienced HBV reactivation, anti-lymphoma treatment was interrupted or delayed. Antiviral prophylaxis was administered to 36 of 45 HBsAg-positive patients and 28 of 62 HBsAg-negative patients (80.0% vs 45.2%; P<0.001).

Patients were treated with Pola-R-CHP (n=89), Pola-R-miniCHP (n=8), or Pola-R-CHP + BTKi (n=10). The CR rate at end of treatment was 80.0% (36/45) for HBsAg-positive patients, compared with 71.0% (44/62) for HBsAg-negative patients (P=0.288). At a median follow-up of 11.3 months, the 1-year PFS rate was 97.5% in the HBsAg-positive group and 92.0% in the HBsAg-negative group (P=0.060) and the 1-year OS rate was 100% in both groups.

 

Conclusion

This multicenter real-world study is the first to characterize HBV reactivation risk in DLBCL patients receiving frontline Pola-R-CHP. Baseline HBV infection status was not associated with reactivation risk or clinical outcomes. The numerically lower reactivation rate observed in HBsAg-positive patients likely reflects their more frequent use of antiviral prophylaxis. Collectively, our findings support the use of Pola-Based Chemoimmunotherapy as frontline therapy for HBsAg-positive DLBCL, and recommend antiviral prophylaxis for patients with serological evidence of prior or current HBV infection.

Mengqiu Wu: No relevant conflicts of interest to declare.